MedTrace Logo

Second-line Chemotherapy in Castration Resistant Prostate Cancer

NCT01558219 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-10-21

No results posted yet for this study

Summary

This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of metastatic castration resistant prostate cancer (mCRPC) patients previously treated with docetaxel containing regimen. The primary endpoint is safety. Secondary endpoints include time to treatment failure, response rate, overall survival and quality of life.

Conditions

Interventions

DRUG

cabacitaxel

Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week

Sponsors & Collaborators

  • Helsinki University Central Hospital

    collaborator OTHER

  • Turku University Hospital

    collaborator OTHER_GOV

  • Kuopio University Hospital

    collaborator OTHER

  • Seinajoki Central Hospital

    collaborator OTHER

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Pirkko-Liisa I kellokumpu-Lehtinen, MD, PhD · Tampere University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01558219 on ClinicalTrials.gov